Robert J Gould Fulcrum Therapeutics, Inc. (FULC) insider trading activity

Robert J Gould is of Fulcrum Therapeutics, Inc.. Currently has a direct ownership of 499,864 shares of FULC, which is worth approximately $1.49 Million. The most recent transaction as insider was on Jan 13, 2023, when has been sold 6,766 shares (Common Stock) at a price of $15.0 per share, resulting in proceeds of $101,490. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 500K

0% 3M change

0% 12M change

Total Value Held $1.49 Million

Robert J Gould Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 13 2023	SELL Open market or private sale	$101,490 $15.0 p/Share	6,766 Reduced 1.34%	499,864 Common Stock
Jun 07 2022	SELL Open market or private sale	$577,909 $8.09 p/Share	71,435 Reduced 12.36%	506,630 Common Stock
Jun 07 2022	BUY Exercise of conversion of derivative security	$560,050 $7.84 p/Share	71,435 Added 11.0%	578,065 Common Stock
Jun 06 2022	SELL Open market or private sale	$197,494 $8.1 p/Share	24,382 Reduced 4.59%	506,630 Common Stock
Jun 06 2022	BUY Exercise of conversion of derivative security	$191,155 $7.84 p/Share	24,382 Added 4.39%	531,012 Common Stock
Jun 03 2022	SELL Open market or private sale	$203,130 $7.95 p/Share	25,551 Reduced 4.8%	506,630 Common Stock
Jun 03 2022	BUY Exercise of conversion of derivative security	$200,320 $7.84 p/Share	25,551 Added 4.58%	532,181 Common Stock
Jun 02 2022	SELL Open market or private sale	$132,177 $7.92 p/Share	16,689 Reduced 3.19%	506,630 Common Stock
Jun 02 2022	BUY Exercise of conversion of derivative security	$130,842 $7.84 p/Share	16,689 Added 3.09%	523,319 Common Stock
Apr 07 2022	SELL Open market or private sale	$135,257 $24.02 p/Share	5,631 Reduced 1.1%	506,630 Common Stock
Apr 07 2022	BUY Exercise of conversion of derivative security	$44,147 $7.84 p/Share	5,631 Added 1.09%	512,261 Common Stock
Apr 05 2022	SELL Open market or private sale	$1,274,912 $24.26 p/Share	52,552 Reduced 9.4%	506,630 Common Stock
Apr 05 2022	BUY Exercise of conversion of derivative security	$412,008 $7.84 p/Share	52,552 Added 8.59%	559,182 Common Stock
Apr 04 2022	SELL Open market or private sale	$173,785 $24.02 p/Share	7,235 Reduced 1.41%	506,630 Common Stock
Apr 04 2022	BUY Exercise of conversion of derivative security	$56,722 $7.84 p/Share	7,235 Added 1.39%	513,865 Common Stock
Apr 01 2022	SELL Open market or private sale	$828,170 $24.03 p/Share	34,464 Reduced 6.37%	506,630 Common Stock
Apr 01 2022	BUY Exercise of conversion of derivative security	$270,198 $7.84 p/Share	34,464 Added 5.99%	541,094 Common Stock
Mar 16 2021	SELL Open market or private sale	$9,807 $12.43 p/Share	789 Reduced 0.16%	506,630 Common Stock
Mar 15 2021	SELL Open market or private sale	$111,729 $12.13 p/Share	9,211 Reduced 1.78%	507,419 Common Stock
Feb 16 2021	SELL Open market or private sale	$118,132 $14.38 p/Share	8,215 Reduced 1.57%	516,630 Common Stock
Jan 20 2021	SELL Open market or private sale	$120,800 $12.08 p/Share	10,000 Reduced 1.87%	524,845 Common Stock

Also insider at

TSBX

Turnstone Biologics Corp.

RJG

Robert J Gould

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FULC shares.

Notify only if

Value

Insider Trading

Get notified when an Fulcrum Therapeutics, Inc. insider buys or sells FULC shares.

Notify only if

Operation

Value

Type

News

Receive news related to Fulcrum Therapeutics, Inc.

Track Activities on FULC

Account